skin squamous cell carcinoma (Cancer)
Information
- Disease name
- skin squamous cell carcinoma
- Disease ID
- DOID:3151
- Description
- "A skin carcinoma that has_material_basis_in squamous cells." [url:http\://en.wikipedia.org/wiki/Squamous-cell_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00954226 | Active, not recruiting | Phase 1 | Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer | August 5, 2009 | March 31, 2025 |
| NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
| NCT03944941 | Active, not recruiting | Phase 2 | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | May 17, 2019 | December 2024 |
| NCT02978625 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | September 27, 2017 | September 1, 2025 |
| NCT02964559 | Active, not recruiting | Phase 2 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | January 27, 2017 | February 27, 2025 |
| NCT03353077 | Completed | N/A | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) | November 21, 2017 | July 14, 2019 |
| NCT01807546 | Completed | Phase 2 | Oral Rigosertib for Squamous Cell Carcinoma | March 2013 | April 2016 |
| NCT03108131 | Completed | Phase 2 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | April 7, 2017 | April 2, 2024 |
| NCT05269381 | Recruiting | Phase 1/Phase 2 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | March 31, 2022 | February 24, 2026 |
| NCT06223659 | Recruiting | Phase 2 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | December 19, 2023 | December 31, 2025 |
| NCT03822988 | Unknown status | ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS | January 21, 2019 | June 20, 2019 |
- Disase is a (Disease Ontology)
- DOID:3451
- Cross Reference ID (Disease Ontology)
- NCI:C4819
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254651007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0553723
- Exact Synonym (Disease Ontology)
- Epidermoid skin carcinoma
- Disase Synonym (Disease Ontology)
- squamous cell carcinoma of skin